Limits...
Polyetherimide-grafted Fe₃O₄@SiO2₂ nanoparticles as theranostic agents for simultaneous VEGF siRNA delivery and magnetic resonance cell imaging.

Li T, Shen X, Chen Y, Zhang C, Yan J, Yang H, Wu C, Zeng H, Liu Y - Int J Nanomedicine (2015)

Bottom Line: Low cytotoxicity and hemolyticity against human red blood cells showed the excellent biocompatibility of the multifunctional nanocomposites, and also no significant coagulation was observed.The nanocomposites maintain their superparamagnetic property at room temperature and no appreciable change in magnetism, even after PEI modification.Our data highlight multifunctional Fe3O4@SiO2/PEI/VEGF shRNA nanocomposites as a potential platform for simultaneous gene delivery and MR cell imaging, which are promising as theranostic agents for cancer treatment and diagnosis in the future.

View Article: PubMed Central - PubMed

Affiliation: Department of Biophysics, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, Sichuan, People's Republic of China.

ABSTRACT
Engineering a safe and high-efficiency delivery system for efficient RNA interference is critical for successful gene therapy. In this study, we designed a novel nanocarrier system of polyethyleneimine (PEI)-modified Fe3O4@SiO2, which allows high efficient loading of VEGF small hairpin (sh)RNA to form Fe3O4@SiO2/PEI/VEGF shRNA nanocomposites for VEGF gene silencing as well as magnetic resonance (MR) imaging. The size, morphology, particle stability, magnetic properties, and gene-binding capacity and protection were determined. Low cytotoxicity and hemolyticity against human red blood cells showed the excellent biocompatibility of the multifunctional nanocomposites, and also no significant coagulation was observed. The nanocomposites maintain their superparamagnetic property at room temperature and no appreciable change in magnetism, even after PEI modification. The qualitative and quantitative analysis of cellular internalization into MCF-7 human breast cancer cells by Prussian blue staining and inductively coupled plasma atomic emission spectroscopy analysis, respectively, demonstrated that the Fe3O4@SiO2/PEI/VEGF shRNA nanocomposites could be easily internalized by MCF-7 cells, and they exhibited significant inhibition of VEGF gene expression. Furthermore, the MR cellular images showed that the superparamagnetic iron oxide core of our Fe3O4@SiO2/PEI/VEGF shRNA nanocomposites could also act as a T2-weighted contrast agent for cancer MR imaging. Our data highlight multifunctional Fe3O4@SiO2/PEI/VEGF shRNA nanocomposites as a potential platform for simultaneous gene delivery and MR cell imaging, which are promising as theranostic agents for cancer treatment and diagnosis in the future.

No MeSH data available.


Related in: MedlinePlus

Evaluating the toxicity of different nanovectors incubated with MCF-7 for 72 hours.Note: The dose of nanovectors ranges from 5–80 μg/mL.Abbreviations: PEI, polyethylenimine; Sc, scrambled; shRNA, small hairpin RNA.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4495783&req=5

f9-ijn-10-4279: Evaluating the toxicity of different nanovectors incubated with MCF-7 for 72 hours.Note: The dose of nanovectors ranges from 5–80 μg/mL.Abbreviations: PEI, polyethylenimine; Sc, scrambled; shRNA, small hairpin RNA.

Mentions: For the ultimate use of nanoparticles as a gene carrier, it is critical that these nanoparticles, after being coated with silica and PEI, retain their low toxicity – ie, the gene carrier should not induce cytotoxic effects.43–45 In order to evaluate the cytotoxicity of the resulting nanoparticles, the viability of human breast cancer MCF-7 cells was tested by MTS assay in the presence of Fe3O4@SiO2, Fe3O4@SiO2/PEI, or Fe3O4@SiO2/PEI/Sc shRNA. As shown in Figure 9, Fe3O4@ SiO2 nanoparticles did not exhibit any detectable cytotoxicity in MCF-7 cells, even after being incubated with a high concentration of nanoparticles for 72 hours. More than 85% of the cells remained viable after incubation with Fe3O4@SiO2/PEI and Fe3O4@SiO2/PEI/Sc shRNA in concentrations of 5–80 μg/mL. This suggests that the Fe3O4@SiO2/PEI nanoparticles showed no significant cytotoxicity, and that they could be used as a carrier for gene therapy.


Polyetherimide-grafted Fe₃O₄@SiO2₂ nanoparticles as theranostic agents for simultaneous VEGF siRNA delivery and magnetic resonance cell imaging.

Li T, Shen X, Chen Y, Zhang C, Yan J, Yang H, Wu C, Zeng H, Liu Y - Int J Nanomedicine (2015)

Evaluating the toxicity of different nanovectors incubated with MCF-7 for 72 hours.Note: The dose of nanovectors ranges from 5–80 μg/mL.Abbreviations: PEI, polyethylenimine; Sc, scrambled; shRNA, small hairpin RNA.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4495783&req=5

f9-ijn-10-4279: Evaluating the toxicity of different nanovectors incubated with MCF-7 for 72 hours.Note: The dose of nanovectors ranges from 5–80 μg/mL.Abbreviations: PEI, polyethylenimine; Sc, scrambled; shRNA, small hairpin RNA.
Mentions: For the ultimate use of nanoparticles as a gene carrier, it is critical that these nanoparticles, after being coated with silica and PEI, retain their low toxicity – ie, the gene carrier should not induce cytotoxic effects.43–45 In order to evaluate the cytotoxicity of the resulting nanoparticles, the viability of human breast cancer MCF-7 cells was tested by MTS assay in the presence of Fe3O4@SiO2, Fe3O4@SiO2/PEI, or Fe3O4@SiO2/PEI/Sc shRNA. As shown in Figure 9, Fe3O4@ SiO2 nanoparticles did not exhibit any detectable cytotoxicity in MCF-7 cells, even after being incubated with a high concentration of nanoparticles for 72 hours. More than 85% of the cells remained viable after incubation with Fe3O4@SiO2/PEI and Fe3O4@SiO2/PEI/Sc shRNA in concentrations of 5–80 μg/mL. This suggests that the Fe3O4@SiO2/PEI nanoparticles showed no significant cytotoxicity, and that they could be used as a carrier for gene therapy.

Bottom Line: Low cytotoxicity and hemolyticity against human red blood cells showed the excellent biocompatibility of the multifunctional nanocomposites, and also no significant coagulation was observed.The nanocomposites maintain their superparamagnetic property at room temperature and no appreciable change in magnetism, even after PEI modification.Our data highlight multifunctional Fe3O4@SiO2/PEI/VEGF shRNA nanocomposites as a potential platform for simultaneous gene delivery and MR cell imaging, which are promising as theranostic agents for cancer treatment and diagnosis in the future.

View Article: PubMed Central - PubMed

Affiliation: Department of Biophysics, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, Sichuan, People's Republic of China.

ABSTRACT
Engineering a safe and high-efficiency delivery system for efficient RNA interference is critical for successful gene therapy. In this study, we designed a novel nanocarrier system of polyethyleneimine (PEI)-modified Fe3O4@SiO2, which allows high efficient loading of VEGF small hairpin (sh)RNA to form Fe3O4@SiO2/PEI/VEGF shRNA nanocomposites for VEGF gene silencing as well as magnetic resonance (MR) imaging. The size, morphology, particle stability, magnetic properties, and gene-binding capacity and protection were determined. Low cytotoxicity and hemolyticity against human red blood cells showed the excellent biocompatibility of the multifunctional nanocomposites, and also no significant coagulation was observed. The nanocomposites maintain their superparamagnetic property at room temperature and no appreciable change in magnetism, even after PEI modification. The qualitative and quantitative analysis of cellular internalization into MCF-7 human breast cancer cells by Prussian blue staining and inductively coupled plasma atomic emission spectroscopy analysis, respectively, demonstrated that the Fe3O4@SiO2/PEI/VEGF shRNA nanocomposites could be easily internalized by MCF-7 cells, and they exhibited significant inhibition of VEGF gene expression. Furthermore, the MR cellular images showed that the superparamagnetic iron oxide core of our Fe3O4@SiO2/PEI/VEGF shRNA nanocomposites could also act as a T2-weighted contrast agent for cancer MR imaging. Our data highlight multifunctional Fe3O4@SiO2/PEI/VEGF shRNA nanocomposites as a potential platform for simultaneous gene delivery and MR cell imaging, which are promising as theranostic agents for cancer treatment and diagnosis in the future.

No MeSH data available.


Related in: MedlinePlus